Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
|Articles|November 4, 2021
The intersection of environment and eczema
Author(s)Linda Stocum, Morgan Ebert, Executive Editor
An interview with Adelaide Hebert, MD, how environmental factors may play a role in flare ups.
Advertisement
Adelaide Hebert, MD, chief of pediatric dermatology at the McGovern Medical School at UTHealth Houston, Texas, highlights how the prevalence of eczema varies and the impact on quality of life. Hebert also highlights how itching can lead to significant disruption in a child’s life, leading to sleep disruption as well as increased discomfort during the hot and humid summer months.
To view the video, click
Advertisement
Related to this article
Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.
A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.
Christina Boull, MD, explains how pediatricians can recognize dermatologic conditions in darker skin tones and address pigment changes and treatment gaps.
Christina Boull, MD, shares recommendations for infant skin care, including choosing gentle cleansers, avoiding irritants, and supporting the skin barrier.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
How pediatricians can reframe vaccine conversations
2
Language barriers linked to lower early peanut introduction rates
3
FDA investigates malignancy risk with SMA gene therapy Zolgensma
4
Risankizumab shows 52-week efficacy in pediatric psoriasis trial
5